Mesoblast stem-cell technology cures 90% of bone fractures, study says

By Elaine Rigoli

Tampa, Fla., Aug. 22 - Mesoblast Ltd. announced positive clinical and preclinical data of its patented adult stem-cell technology for the treatment of long bone fractures.

In both trials, Mesoblast said its stem cells were highly effective in combination with the latest Food and Drug Administration-approved carrier materials provided by Mesoblast's collaborative partner, a global orthopedic corporation.

The data showed a 90% healing in tibial defects compared with controls, the company noted.

Mesoblast is a biotechnology company based in Melbourne, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.